S
Spruce Biosciences
Developing novel therapies for rare endocrine diseases, starting with our lead product candidate for the treatment of congenital adrenal hyperplasia
About Spruce Biosciences
Spruce Biosciences is a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine disorders. The company primarily targets conditions like congenital adrenal hyperplasia (CAH), a rare disorder that impairs cortisol production. Unlike existing treatments that rely on high-dose steroids and come with significant side effects, Spruce Biosciences is pioneering non-steroidal alternatives. Their lead product candidate, Tildacerfont (SPR001), aims to correct hormone imbalances without the adverse effects associated with steroidal treatments.
Spruce Biosciences operates in the biotechnology sector, specifically within the niche market of rare endocrine diseases. Their business model revolves around the research and development (R&D) of novel small molecule treatments, which they advance through clinical trials. The company generates revenue through funding rounds, such as Series B financing, and aims to monetize its products through eventual FDA approval and commercialization.
The primary clients for Spruce Biosciences are patients suffering from rare endocrine disorders, healthcare providers, and potentially pharmaceutical companies interested in licensing their therapies. The company’s mission is to improve the quality of life for patients who have been underserved by existing treatments.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2020
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 86.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Lead Generation, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2026 | $69M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Jan 2026 | $0 | — | Avenue Capital Group | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$35M | — |
| 2025 | $0 | -100% | −$35M | — |
| 2024 | $4.9M | -51.3% | −$53M | -1072.8% |
| 2023 | $10M | — | −$47M | -469.5% |
| 2022 | $0 | — | −$46M | — |
| 2021 | $0 | — | −$42M | — |
| 2020 | $0 | — | −$29M | — |
Growth signals
Latest recorded traffic for Spruce Biosciences is 90 monthly website visits, down 93.1% over the last three months. Spruce Biosciences's team grew 56.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Novo Holding
RiverVest Venture Partners
Abingworth
HealthCap
Aisling Capital
Rock Springs Capital
Novo Holdings
Omega Funds
Series B and later1 investor entered at this stage
Avenue Capital Group
Other known investors2 additional known investors
5AM Ventures
Armistice Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spruce Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spruce Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.